Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
: u9 K9 p! F6 ~6 d C# {7 c3 T. h$ n, Y
5 V2 _0 `. }, P# HSub-category:
, e7 i2 R; K. w8 [" e- _( n, GMolecular Targets F2 W: v3 M3 e% V* k
1 B$ B) B6 c4 K1 c# C
1 o, `5 R% ?% H" S7 d5 PCategory:
' Y; A, E7 W" G+ a( {5 RTumor Biology - E9 Y8 g0 v9 ~
2 V9 K. {# N( c! h k6 @+ |8 b! |- h$ t
Meeting:6 c6 D/ i) `0 L( R
2011 ASCO Annual Meeting 1 g( @! m; I2 [6 N8 @$ E Y
* Z5 E$ X3 K( G+ X D* ^
2 z" d, ]7 k, N8 L8 WSession Type and Session Title:8 k p4 L) M) G) m% A
Poster Discussion Session, Tumor Biology
+ ?+ U5 D W) B* c$ A4 h' k/ }( ^! o" L6 G
% M, e. a4 t4 V W( j( G2 G6 J
Abstract No:
# N e% x/ p( ?( A10517
8 v& ]" Y1 \1 R* m$ @& a7 K- [0 r; d. G
, _: Z0 f# D$ MCitation:
m: D$ S9 y5 b4 p$ oJ Clin Oncol 29: 2011 (suppl; abstr 10517) % @/ H. b7 a& ^' _' U5 G! v6 J
( g: f0 ]1 T. U; l# R+ w7 ]
# }4 C! U j0 h! S2 t t; \& OAuthor(s):
/ I/ D# Y/ e2 s. N& d- DJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
8 o5 L A8 Y! _) {1 g6 E+ s! Z8 x: E, W4 }7 P6 y) [
6 a7 z' \" R) m- H* D4 l& O) D5 A: x1 @. L! g5 l" A% t4 {
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 i4 S% o/ q- H2 D1 C5 Q
/ \6 i7 e1 N0 U3 T9 _$ \Abstract Disclosures
* M3 @( b: S4 B/ e* R, m
: D$ ^ y) @4 m. K# O2 c1 QAbstract:, b( T6 k$ d$ O9 ?
7 I J- W6 H Q5 x h* x
O3 W# `# ?' Z3 `" O) }Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 S3 z7 r0 d) x( n" `2 K) ~0 p" f
$ R) Z q3 |1 O, V" Q( q# Y& J
4 B& [# k7 M! x: W! a. L7 |
|
癌痛患者福音「人间有情」-李嘉诚基
李嘉诚先生年少即历经忧患，认为对无助的人给予帮助是世上最有意义的事情，教育
完成手术，病理也出来了，烦请各位老
之前因为心脏问题，去心内造影，前降支75%狭窄，回到心胸外科手术，目前主治医生说是
CSCO/NCCN双指南推荐！MET突变肺癌患
你知道吗？人体内存在一种掌控着生命密码的特殊蛋白——MET蛋白。正常的MET蛋白如同精
求助： 阿美耐药, 化疗效果不好,身体
2022年7月确诊 右肺上叶近肺门肿块 纵隔淋巴结肿大 左侧锁骨淋巴结转移
求助贴，奥西替尼一年多后CT有进展，
我父亲今年79，23年12月穿刺病理诊断为肺腺癌晚期。
基因检测EGRF19外显因子突变，丰
& ]8 d: ^ P( j% E
显身卡
